Australia vs. Latin America for First-in-Human Medical Device Trials (2026)

Australia is a good first-in-human destination. For most early-stage device sponsors, it is not the best-fit one — and the reasons are structural, not a judgment on quality.

September 2, 2026

8

min read

By

Julio G. Martinez-Clark, CEO, bioaccess®

Australia

Latin America

First-in-Human

Medical Devices

TGA

Panama

Regulatory

What does Australia genuinely get right?

Start with the concession, because it is real and because pretending otherwise would cost you money. Australia is a legitimately strong early-phase destination, and sponsors who choose it are not making a mistake.

• TGA CTN notification is genuinely fast. Getting an early-stage device study on the regulatory record in Australia is among the quickest processes in the developed world.
• Data quality is high. Australian sites, investigators, and ethics committees produce clean, well-documented, audit-ready datasets that regulators trust.
• The R&D tax incentive is a real program, not marketing. A refundable 43.5% offset is meaningful capital for a company burning runway.

So this is not an argument about quality. It is an argument about fit for purpose. A first-in-human device study has four constraints that dominate everything else: how fast you can open, how fast you can enroll, how much cash leaves the account and when it comes back, and whether the resulting dataset survives contact with your US and EU launch requirements. On three of those four, geography decides the outcome — and that is where Latin America pulls ahead.

How do Australia and Latin America compare head to head?

What is the true net cost after the R&D tax incentive?

This is where most Australia comparisons quietly cheat. The headline is "43.5% back," and sponsors model it as an immediate discount. It is not. The 43.5% offset is refundable only for companies with aggregated turnover under A$20M; above that threshold it becomes a 38.5% non-refundable offset. To claim it at all you need an Australian incorporated entity or permanent establishment, AusIndustry registration, and local legal and accounting support. And the money arrives 12-18 months after the spend, because it follows tax-year lodgment.

For a venture-backed device company, a rebate that lands 12-18 months late is not a discount — it is a loan you make to your own program at the worst possible moment. Latin America is pay-as-you-go at roughly the post-rebate net. You do not stand up an entity, you do not carry the eligibility risk, and you do not wait a fiscal cycle to see the cash. We break the arithmetic down line by line in the true cost of Australia's 43.5% R&D tax incentive.

Why does recruitment catchment favor Latin America?

Australia is roughly 86% urbanized. This is not a claim that it lacks cities — it plainly does not. The claim is about absolute catchment and density. Australia's five largest metros — Sydney 5.6M, Melbourne 5.4M, Brisbane 2.8M, Perth 2.5M, and Adelaide 1.5M — total about 17.9M people, which is fewer than metro Sao Paulo alone at roughly 23M. Mexico City is roughly 23M. Buenos Aires is about 16.7M. Bogota is about 12.8M, more than double Sydney.

Density compounds it. Australia runs about 3 people per square kilometer, against roughly 25 in Brazil, 46 in Colombia, 60 in Panama, 230 in the Dominican Republic, and 300-plus in El Salvador. Low-density metro sprawl shrinks the practical recruitment radius around any single clinic: the number that matters is not the metro's population on paper, it is how many eligible patients can plausibly get to your site repeatedly for follow-up. See the catchment math behind Australian recruitment and how it maps to TGA CTN versus Latin America on first-patient-in timelines.

Approval speed and enrollment speed are different products. A fast notification with a slow enrollment curve still ships your dataset late. Sponsors who learned that the hard way are the subject of the three years lost in Australia before moving first-in-human to Latin America.

Why does Fitzpatrick skin-type diversity matter now?

Australia's population is predominantly Fitzpatrick phototypes I-III. Meanwhile, US and EU launches increasingly require evidence across Fitzpatrick I-VI — a hard constraint for optical, energy-based, imaging, and wearable-sensor technologies whose performance varies with skin pigmentation. If your first-in-human dataset covers only part of the range, you are not finished; you are one region short.

A multi-arm Latin American design solves it inside one protocol. Panama plus Brazil plus the Dominican Republic delivers the full Fitzpatrick range under a single set of endpoints, a single monitoring plan, and a single dataset. More detail in Fitzpatrick skin-type diversity in clinical trials.

How much do travel and time zones really cost you?

Early device studies are proctored studies. Your engineer, your clinical lead, and often your founder are physically present for the first cases. Australia is 20-plus hours of travel from the US East Coast with a 14-16 hour offset, which means every proctored case costs several working days on each side plus recovery. bioaccess® sites in Latin America are 3-7 hour flights from Miami and sit in US-adjacent time zones: proctor a Tuesday case, sleep at home Wednesday. Same-day calls with the site happen during your working hours, not at midnight.

Will the FDA accept the data?

Yes — by design. Under 21 CFR 812.28 (final rule 2018), the FDA accepts clinical data from studies conducted outside the United States under good clinical practice. This is not an exception carved out reluctantly; it is the framework the agency built for exactly this purpose. Two public bioaccess® client examples show the path end to end: ReGelTec ran its HYDRAFIL first-in-human study in Colombia in 20 patients in 2020, received FDA Breakthrough Device designation in December 2020, and moved into a US IDE; enVVeno Medical ran its VenoValve first-in-human study in Colombia in 11 patients and advanced to the US pivotal SAVVE study on a PMA path. Read the mechanics in our first-in-human CRO overview.

When is Australia still the right answer?

Be honest about this too. If your company is under the A$20M turnover threshold, already has an Australian entity or permanent establishment, can absorb a 12-18 month cash lag without a financing consequence, needs a small cohort your Australian site can plausibly enroll, and has no Fitzpatrick IV-VI requirement in your launch markets, Australia is a defensible choice with excellent data quality.

Change any one of those variables — bigger cohort, tighter runway, pigmentation-sensitive technology, no local entity, heavy proctoring — and the fit-for-purpose answer moves. That is the whole argument. For the full landscape, see alternatives to Australia for first-in-human trials in 2026, our Panama clinical trials pathway, and how the same infrastructure carries you into Latin American market access after the study closes.

Frequently asked questions

What is the fastest next step?

Send us your device, your cohort size, and your target first-patient-in date. We will tell you which countries fit, what the realistic activation timeline looks like, and where your protocol will struggle — including the cases where Australia is the better answer. Get a first-in-human feasibility read in 72 hours.

Get your feasibility read

See how we run first-in-human